Biogen To Submit Spinraza To UK's NICE For SMA, While Australia Wants More Data

Biogen’s Spinraza for the rare disease spinal muscular atrophy is to be assessed by NICE, the UK HTA body for England and Wales. In the interim it will be made available under a managed access deal. The product is also being assessed by Australia’s PBAC, which has asked for more cost-effectiveness data and may require a reduction in the company’s proposed price.